We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Stanford psychiatrist removed from drug study.
- Abstract
The article elaborates the removal of Alan Schatzberg, chairman of psychiatry, from the Standford University in Great Britain. The institution removed Schatzberg from its position as principal investigator from a National Institute of Mental Health (NIMH) grant because of his impartiality in overseeing the grant in the investigation on the use of mifepristone manufactured by Corcept Therapeutics. The U.S. Senate investigators discovered Schatzberg owns 2.7 million shares worth nearly US$6 million. According to Debra Zumwalt, vice-president and general counsel of Standord, despite its belief that Stanford, NIMH and Schatzberg have handled the grant in accordance with the regulations and policies, his position can create an appearance of conflict of interest.
- Subjects
UNITED States; SCHATZBERG, Alan; CORCEPT Therapeutics Inc.; MIFEPRISTONE; BUSINESS ethics; CONFLICT of interests; CLINICAL medicine; PSYCHIATRY; NATIONAL Institute of Mental Health (U.S.)
- Publication
Nature, 2008, Vol 454, Issue 7205, p679
- ISSN
0028-0836
- Publication type
Article
- DOI
10.1038/454679a